Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

    BMJ Open Date published:

  • Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

    Hypertension Date published:

  • China Kidney Disease Network (CK-NET) 2015 Annual Data Report

    Kidney International Supplements Date published:

  • Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop

    Kidney International Date published:

  • Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

    The Lancet Diabetes & Endocrinology Date published:

  • New hypoglycemic agents and the kidney: what do the major trials tell us?

    F1000Research Date published:

  • Glucose lowering and the kidney: are all drug classes equal?

    The Lancet Diabetes & Endocrinology Date published:

  • Reducing cardiovascular risk in people with diabetes and kidney disease

    Medical Journal of Australia Date published:

  • ACCORDION: Ensuring That We Hear the Music Clearly

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

    Circulation Date published:

  • New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

    Diabetes, Obesity and Metabolism Date published:

  • Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease

    Cochrane Database of Systematic Reviews Date published:

  • Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

    The Lancet Diabetes & Endocrinology Date published:

  • Letter by Matthews et al Regarding Article, “Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist”

    Circulation Date published:

  • Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

    Circulation Date published:

  • Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial

    Diabetes Date published: